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ABSTRACT
The presence of IL-1 in human cancers is associated with aggressive tumor 
biology but its prognostic value is unknown. We studied whether IL-1α expression is 
a prognostic marker of distant metastasis in patients with head and neck squamous 
cell carcinoma (HNSCC). IL-1α mRNA and protein levels were determined in tumor 
samples and cancer cell lines using RT-PCR and ELISA. The effects of constitutive IL-
1α expression by tumor lines were characterized. IL-1α mRNA and protein secretion 
were higher in tumor samples from patients who later developed distant metastasis 
than in patients who did not. By using distant metastasis as a dependent variable, 
patients were classified into two categories of IL-1α transcript-levels. The high-IL-
1α group had a significantly lower five-year distant metastasis-free survival than the 
low-IL-1α group [70.0% (CI 95%: 55.9-84.1%) vs 94.7% (CI 95%:90.2-99.2%)]. 
When IL-1α transcript-levels were combined with clinical factors related to tumor 
metastasis, the predictive power of the model increased significantly. Additionally, 
transcript levels of IL-1α correlated significantly with those of the IL-1 family 
genes and genes related to the metastatic process. IL-1 treatment of microvascular 
endothelial cells increased adhesion of HNSCC cells but no differences were found 
based on constitutive IL-1α expression by tumor cells. Nevertheless, IL-1α produced 
by tumor cells effectively increased their transmigration across the endothelium. We 
found a significant relationship between IL-1α expression and development of distant 
metastasis in HNSCC patients. IL-1α expression could help to define a subset of 
patients at high risk of distant metastasis who could benefit from adjuvant treatment.
INTRODUCTION
Loco-regional control of head and neck squamous 
cell carcinoma (HNSCC) has improved in the last 
decades thanks to more aggressive surgical techniques, 
improvements in radiotherapy, and the development of 
new antitumoral drugs. Paradoxically, these advances 
have not translated into a concomitant increase in survival. 
The appearance of distant metastasis is one of the most 
relevant factors responsible for this divergence [1].
Metastatic spread is a complex sequential process 
which depends on the biology of the tumor. Tumor 
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metastasis is a sequential multi-step process requiring 
detachment of individual tumor cells from the adjacent 
tumor and stromal cells, the invasion and progression 
through the extracellular matrix, the intravasation into 
lymphatic or vascular vessels, survival in regional or 
systemic circulation, and implantation and proliferation 
into regional neck nodes or distant tissues [2, 3]. All these 
steps are tightly regulated by cell-associated and soluble 
mediators. Tumors secrete soluble factors such as growth 
factors, cytokines and chemokines with autocrine and 
paracrine biological activities. These factors not only exert 
autocrine actions but also interact with the surrounding 
stromal and endothelial cells, exerting relevant biological 
effects. One of these effects is the promotion of metastasis, 
an effect which has been related with several molecules 
expression, such as desmoplakin [4], E-cadherin and 
vimentin [5, 6], αB-crystallin (HspB5) [7] or IL-α [8].
IL-1 is a pleiotropic pro-inflammatory cytokine 
that exhibits biological activities supporting its role in 
tumor growth and metastasis. The IL-1 family includes 
three members that bind to the same receptor. Two of 
the members are active, IL-1α and IL-1β, and the third 
member is an antagonist, IL-1Ra. When IL-1Ra binds to 
the IL-1 receptor, no signal is transduced and there is no 
biological response. Although IL-1α and IL-1β are coded 
by different genes, their biological activities are identical. 
Two receptors of the immunoglobulin superfamily (IL-1R1 
and IL-1R2) selectively bind IL-1. IL-1R1 is biologically 
active and it is ubiquitously expressed, while IL-1R2 acts 
as an IL-1 scavenger. Following binding of IL-1 to IL-1RI 
the IL-1 receptor accessory protein (IL-1RaP) is recruited 
to form a protein complex. This heterodimeric complex 
triggers the IL-1 signaling pathway that ultimately leads 
to the activation of a number of transcription factors [9]. 
IL-1 induces several pro-metastatic genes, such 
as matrix metalloproteinases and endothelial adhesion 
molecules, and pro-angiogenic factors such as VEGF, 
chemokines, prostaglandin (PG) E2, growth factors, and 
TGFβ [10]. Expression of IL-1 is high in some tumors 
[11], including HNSCC [12-14]. Studies with experimental 
models of melanoma [15], pancreatic carcinoma [16, 17], 
lung carcinoma and colon cancers [18] have shown that 
local production of IL-1 influences metastatic capacity 
and tumour growth [8, 19]. Moreover, tumors that produce 
high levels of IL-1 have been associated with a poor 
prognosis [11]. IL-1 induces angiogenesis in vivo and in 
vitro [20].
Data concerning the role of IL-1 expression in the 
appearance of distant metastasis have not been evaluated 
in HNSCC patients. The aim of the present study was to 
assess IL-1 expression in pre-treatment biopsy samples of 
HNSCC patients, and to evaluate the prognostic capacity 
of IL-1 levels in the prediction of the appearance of distant 
metastasis. 
RESULTS
IL-1α transcript levels are associated with the 
presence of distant metastasis
Table 1 shows the characteristics of the patients 
included in the study. The median follow-up time of 
patients was 4.8 years (range, 2.3-10 years). The median 
follow-up time of patients was 4.8 years (range, 2.3-10 
years). Local failure of the tumor occurred in 46 (29.9%) 
patients during the follow-up period, regional failure was 
detected in 23 (14.9%) patients, and distant metastasis in 
18 (11.7%) patients. We examined the expression of IL-
1α in tumoral samples from HNSCC patients with and 
without distant metastasis by quantitative RT-PCR (Figure 
1A). Patients with distant metastasis showed significantly 
higher levels of IL-1α than those without metastasis. 
Using appearance of distant metastasis as the dependent 
variable, CART analysis classified patients into two 
categories, low (n = 102, 66.2%) and high (n = 52, 33.8%) 
expression level of IL-1α. The five-year distant metastasis-
free survival was statistically significant between the two 
groups (p < 0.001), being 70.0% (CI 95%: 55.9-84.1%) for 
patients with an IL-1α high-expression level and 94.7% 
(CI 95%:90.2-99.2%) for patients with an IL-1α low-
expression level. Figure 1B shows the distant metastasis-
free survival curves corresponding to the CART 
classification. Table 2 shows the results of the multivariate 
study considering the appearance of distant metastasis as 
the dependent variable. The expression level of IL-1α 
was the only variable that was significantly related to the 
appearance of distant metastasis. Considering patients 
with a low-level expression of IL-1α as the reference 
category, patients with high expression of IL-1α had a 5.3-
fold higher risk of appearance of distant metastasis (CI 
95%: 1.8-15.8). 
We then analyzed the relationship between the risk 
of appearance of distant metastasis and the category of 
IL-1α expression in the group of 99 patients with loco-
regional control of the disease. In this subset of patients, 
the expression level of IL-1α showed the same relationship 
with the development of distant metastasis. The five-year 
distant metastasis free survival was 75.2% (CI 95%:59.4-
91.0%) for patients with a high-IL-1α and 94.3% (CI 
95%:88.9-99.7%) for patients with a low-IL-1α; the 
difference was statistically significant (p = 0.01). 
We defined a cohort of patients with a high risk 
of appearance of distant metastasis based on clinical 
variables. These variables included locally advanced 
tumors (T4), advanced regional spread (N2-3), and 
extracapsular spread. Patients that met one or more of 
these criteria constituted the high risk group (n = 60), 
while the low risk group did not present any of the criteria 
(n = 94). The low risk group showed a 93.9% (CI 95%: 
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88.6-99.2%) five-year distant-metastasis-free survival 
while the high risk group dropped to 71.9% (CI 95%: 
58.2-85.6%); the difference was statistically significant 
(p = 0.001). IL-1α expression in the clinical high risk 
group (n = 60) retained prognostic power. Five-year 
distant-metastasis-free survival for patients with low-IL-
1α expression (n = 33) was 93.5% (IC 95%: 84.9-100%), 
dropping to 49.1% (IC 95%: 26.6-71.6%) for patients with 
high-IL-1α expression (n = 27, p = 0.002). 
Information regarding HPV status was available for 
40 of the 49 patients with an oropharyngeal carcinoma. 
Only 20% (n = 8) of oropharyngeal tumors were HPV 
Table 1: Characteristics of the patients included in the study. 
Characteristics Nº (%)
No Patients 154
Age (years)
Median
Range
62.5
38.1-92.3
Sex 
Male
Female
139 (90.3%)
15 (9.7%)
Tumor location 
Oral cavity/oropharynx
Larynx/hypopharynx
65 (42.2%)
89 (57.8%)
T category
cT1-2
cT3-4
80 (51.9%)
74 (48.1%)
N category
cN0
cN+
90 (58.4%)
64 (41.6%)
Tumor differentiation
Well differentiated
Moderately differentiated
Poorly differentiated
9 (5.8%)
128 (83.1%)
17 (11.0%)
Treatment
Surgery ± radiotherapy
(Chemo)-radiotherapy
43 (27.9%)
111 (72.1%)
Figure 1: IL-1α expression is associated with the presence of distant metastasis. A. Box plot graph of IL-1α transcript levels 
relative to β-actin (x1000) in HNSCC samples as a function of appearance of distant metastasis; metastasis (n = 18) and no metastasis (n 
= 136); *, p < 0.05; when compared with the no-metastasis group of patients. B. Five-year distant metastasis-free survival according to the 
category of the IL-1α mRNA levels; low IL-1α n = 102 and high IL-1α n = 52.
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positive (7, HPV-16 and 1 HPV-51). There were no 
significant differences regarding IL-1α expression as a 
function of HPV status (p = 0.377).
Secretion of IL-1α by tumor samples was 
significantly higher in patients that developed 
distant metastasis
We analyzed IL-1α production ex vivo by tumor 
samples from 35 patients (28.6%) included in the study, 10 
of whom developed distant metastasis during the follow-
up period. The results in figure 2A show that the protein 
levels of IL-1α secreted by tumor samples of patients 
that developed distant metastasis were significantly 
higher. When we applied the CART method using the 
development of distant metastasis as the dependent 
variable, the resulting tree distributed the patients into two 
groups according to IL-1α concentration in the secretome. 
The high IL-1α concentration group (n = 8) showed a 
significantly higher risk of distant metastasis than the low 
IL-1α concentration group (n = 27). Figure 2B shows the 
metastasis-free survival curve obtained with the IL-1α data 
from the secretome analysis.
Table 2: Results of the multivariate study considering the appearance of distant metastasis 
as the dependent variable (HR: hazard ratio).
Characteristics HR CI 95% HR P
Location
Oral cavity/oropharynx
Larynx/hypopharynx 
1
1.56
0.58-4.19 0.37
Local extension
cT1-2
cT3-4
1
0.66
0.23-1.88 0.44
Regional extension
cN0
cN+
1
2.33
0.82-6.60 0.11
Treatment
Surgery ± radiotherapy
(Chemo)-radiotherapy
1
0.53
0.20-1.44 0.21
IL-1α
Low 
High 
1
5.35
1.81-15.84 0.002
Figure 2: Levels of IL-1α secreted by tumor samples were higher in patients that developed distant metastasis. A. 
Release of IL-1α protein by HNSCC samples as a function of appearance of distant metastasis; tissue fragments were incubated for 48 hours 
in a cell incubator. Thereafter, IL-1α in the media was analyzed; metastasis (n = 10) and no metastasis (n = 25); *, p < 0.05; when compared 
with the no-metastasis group of patients. B. Five-year distant metastasis-free survival according to the category of the IL-1α secreted; low 
IL-1α n = 27 and high IL-1α n = 8 
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Expression of IL-1α in HNSCC tumor samples 
correlates with transcript levels of genes related 
with the metastatic process
We studied the correlation between the expression 
of IL-1α and the expression of other related genes of the 
IL-1 family. Results in Figure 3 show a highly significant 
statistical association between IL-1α and either IL-1β or 
IL-1Ra. Moreover, we observed that the variation in levels 
of IL-1α correlated with that of IL-1 receptors, particularly 
with IL-1R2.
We next determined transcript levels of some 
genes related with the metastatic process that it is known 
to be regulated by IL-1. Results in figure 4 indicate 
that most of these genes were enhanced in the high IL-
1α group. Interestingly, the most enhanced expression, 
besides the IL-1 family genes, were the genes involved 
in angiogenesis, such as MMP-9, PGE2 biosynthetic 
machinery (COX-2 and mPGES-1), VEGF and IL-8. This 
was consistent with a significant high expression of the 
endothelial cell marker von Willebrand Factor (vWF) in 
the high IL-1α group of patients. In contrast, we found 
no statistically significant differences between patients 
stratified by the IL-1α expression in other IL-1α-related 
pathways, such as the chemokine for stem cells SDF-
1 or SDF-1-receptor (CXCR4), the matrix degrading 
enzyme MMP-2, or the epithelial-mesenchymal transition 
promoter TGFβ (Figure 4).
Figure 3: Statistical correlation between transcript levels of IL-1α and those of IL1 signaling pathway genes. The 
Pearson Product Moment Correlation after logarithmic transformation of data was applied; n = 154.
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Expression of IL-1α increases trans-endothelial 
cell migration but not affects adhesion of HNSCC 
cells lines to MVEC
Seven human HNSCC cell lines (CAL-27, FaDu, 
SCC-4, SCC-9, SCC-22a, SCC-22b and SCC-25) were 
studied for the expression of IL-1α in terms of mRNA 
and protein to find two cell lines expressing high and 
low levels of the cytokine. The cytokine protein was 
measured simultaneously in both the culture supernatants 
(for secreted cytokine) and the lysates made from the 
remaining cells (for cell associated cytokine). All HNSCC 
cell lines assayed, except SSC-9, expressed IL-1α but the 
levels varied from one line to another (data not shown). 
We chose two tongue carcinoma cell lines SCC-4 and 
Figure 4: Expression of IL-1α in HNSCC tumor samples correlates with transcript levels of genes related with the 
metastatic process. Box plot of mRNA transcript levels of several genes related or regulated by IL-1 in tumor samples stratified by 
low and high levels of IL-1α. Low IL-1α n = 102 and high IL-1α n = 52; *, p < 0.05; **, p < 0.01 and ***, p < 0.001 when compared with 
low-IL-1α.
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SCC-9. SCC-4 produced high amounts of IL-1α and, to a 
much lesser extent IL-1β. In SCC-9, levels of both forms 
of IL-1 were almost undetectable (Figure 5).
We then examined the influence of IL-1α expression 
on the ability of tumor cells to adhere to MVEC and 
MVEC previously treated with 10U/mL of human 
recombinant IL-1β for 24 hours. The results in Figure 6 
show that both SCC-4 and SCC-9 cells adhere to MVEC 
and treatment of MVEC with IL-1β significantly increased 
the adhesion of tumor cells, but no differences were found 
between the two cell lines. Afterwards, we tested the ability 
of these cell lines to migrate across a MVEC monolayer in 
vitro. Results depicted in the left panel of Figure 6B show 
that both cell lines were able to migrate across the MVEC 
barrier, and although the transmigration of SCC-4 was 
higher in terms of the mean, the difference between the 
two cell lines failed to achieve statistical significance (p = 
0.08). Nevertheless, the presence of human recombinant 
IL-1Ra significantly reduced transmigration of SCC-4, 
whereas it failed to block SCC-9 transmigration. While 
the above observation suggested a correlation between IL-
1α expression and tumor cell transmigration, we further 
tested the effect of IL-1α knockdown and overexpression 
on the trans-MVEC migration. We found that silencing 
of IL-1α in SCC-4 significantly reduced transmigration 
across MVEC and overexpression of IL-1α in SCC-9 
resulted in a significant increase of cell transmigration 
(Figure 6B). However, neither IL-1α knockdown nor 
IL-α overexpression significantly affected tumoral cells 
adhesion to matrix extracellular proteins (data no shown).
DISCUSSION
Our study in a large cohort of HNSCC patients 
provide evidence that high levels of IL-1α expression are 
associated with a higher risk of distant metastasis, in terms 
of both local transcript in the primary tumor and ex vivo 
protein production by primary tumor samples. 
The appearance of distant metastasis is a major 
cause of death in head and neck cancer patients. The rate 
Figure 5: Secreted and intracellular levels of IL-1α and IL-1β by HNSCC cell lines. Cells were incubated for 48 hours in 1% 
FBS. Thereafter, IL-1α and IL-1β were analyzed in the media and in the cell lysates (n = 3). Representative immunofluorescent staining for 
IL-1α is also shown (bars 50μm). 
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of clinical progression, including the risk of metastasis 
and relapse, can be estimated on the basis of clinical 
information such as tumor location, lymph node status 
at diagnosis and extracapsular spread of the lymph 
nodes [21-23]. However, only a few studies have related 
biomarker expression with the risk of distant metastasis in 
HNSCC as, for example, down-regulation of desmoplakin 
[4], cytokeratin 19 [24] or E-cadherin [5, 6], and over-
expression of αB-crystallin [7].
Previous reports have emphasized the increased 
risk of distant metastasis in patients with locoregional 
failure after initial treatment [25, 26]. This increased 
risk may be due to unsuccessful treatment or a sign of 
tumor aggressivity. Furthermore, patients who achieve 
locoregional control of the primary tumor may also later 
develop metastasis if there is subclinical metastatic spread 
Figure 6: Expression of IL-1α influences trans-endothelial cell migration but not adhesion in HNSCC cells lines. A.- 
Effect of IL-1 on the HSCC cells adhesion to MVEC. MVEC cultured in 12-well cell culture plates were treated or not with 10 U/mL IL-1β 
for 24 hours. MVEC were washed and 1×106 fluorescent labeled tumoral cells were added and incubated at 37ºC for 30 minutes. Adherent 
cells were solubilized and fluorescence was measured; SCC-4 n = 3; SCC-9 n = 7; mean±SEM; **, p < 0.01 when compared with controls. 
B.- Effect of the presence of IL-1Ra (left panel; n = 7; **, p < 0.01 when compared with cells in the absence of IL-1Ra), IL-1α knockdown 
(middle panel; n = 6; *, p < 0.05 when compared with random) and IL-1α overexpression (right panel; n = 5; *, p < 0.05 when compared 
with empty vector) on the trans-MVEC migration of HNSCC cell lines. MVEC were plated onto 24-well cell culture inserts 8-µm. Once 
confluence was reached, 2.5×105 fluorescent labeled tumoral cells were added to the upper well of the inserts and allowed to transmigrate 
through the endothelium for 24 h. Migratory cells were lysed and fluorescence was measured. Left panel in the absence (-hIL-1ra) or in 
the presence (+ hIL-1ra) of 250 ng/mL recombinant human IL-1Ra; middle panel SCC-4 transfected with siRNA targeting IL-1α (siIL-1α), 
negative control siRNA (Random); right panel SCC-9 transfected with plasmid encoding full-length IL-1α pCMV6-IL-1α (pCMV6-AC-
IL) or Precision Shuttle mammalian vector pCMV6-AC (Vector).
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at the time of locoregional treatment. Our results showed 
that in both clinical settings, with or without locoregional 
relapse, expression of IL-1α has significant prognostic 
power. 
In the tumor milieu, IL-1 induces expression of 
various metastatic mediators such as MMP, VEGF, IL-
8, IL-6, TNFα, and TGFβ (reviewed in 9,13,30,31). Our 
correlation study showed that variations in tumor IL-1α 
transcript levels were associated not only with variations 
of IL-1 family genes, but also with several genes related 
to neovascularisation. This suggests that IL-1α stimulates 
vascularization, thus facilitating tumor cell transmigration. 
The fact that IL-1 induces angiogenesis in vitro, mainly 
promoting PGE2 biosynthesis, supports this suggestion 
[20]. We previously showed that HNSCC cell supernatant 
induced COX-2 and mPGES-1 in fibroblasts and MVEC 
mainly by means of IL-1 receptor activation, increasing 
PGE2 production and activity [14, 27]. Also, IL-1α 
released by tumor cells stimulates the proliferation of 
carcinoma-associated fibroblasts and increases cytokines 
secretion from fibroblasts, which in turn promotes cancer 
progression [8]. Taken together, these findings show that 
IL-1α is an important factor in the crosstalk between 
tumoral cells and surrounding stroma and endothelial 
cells.
The first step in the process of metastatic spread 
is the binding of tumoral cells to endothelium. IL-1 
increases adhesiveness of endothelial cells up-regulating 
the expression of endothelial adhesion molecules. Here, 
we show that treatment of MVEC with IL-1 enhanced 
adhesion of tumoral cells. We also show a correlation 
between IL-1α expression and tumor cell transmigration. 
IL-1α produced by tumor cells effectively increased its 
transmigration across the endothelium. This conclusion 
is based on the fact that the presence of IL1Ra resulted 
in a statistically significant decrease in trans-endothelial 
migration of an IL1-producing cell line tested but it had 
no effect on non-IL-1-producing cells. In addition, IL-1α 
knockdown in the IL1α-producing cell line significantly 
reduced transmigration, while overexpression of IL-1α in 
the non-IL-1α-producing cell line significantly increased 
cell transmigration. 
However, tumors are heterogeneous population of 
cells from diverse origins, such as stem cells, stromal cells, 
endothelial cells and a wide range of immune cells. IL-1 
is secreted by tumor cells, but others, particularly immune 
cells infiltrating tumor, may contribute to the levels of IL-1 
in the tumor microenvironment [10, 19, 28, 29]. Further 
research will be required to relate the degree of infiltrating 
cells and their activation with the tumor levels of IL-1 
and therefore their role in metastasis mediated by IL-1 in 
HNSCC.
The combination of clinical data with biomarkers 
such as IL-1α could help us to define a population at high 
risk for distant metastasis. In this study, patients with a 
high expression level of IL-1α and clinical high risk 
prognostic factors showed a 50% risk of distant metastasis 
in five years. These patients could benefit from adjuvant 
treatments that help sterilize the micrometastatic disease 
thereby improving disease-free survival. Nevertheless, 
some limitations of the study should be taken into 
account. This is a single institution retrospective study 
with a limited number of patients. Independent validation 
studies are required to demonstrate the utility of IL-1α 
expression as a biomarker for distant metastases in this 
clinical setting.
In conclusion, our results show a significant 
relationship between IL-1α expression and the 
development of distant metastasis in HNSCC patients. 
The combination of clinical data, such as locoregional 
extension or extracapsular spread and IL-1α expression 
could help us to define a group of patients with a high 
risk of distant metastasis. Adjuvant treatment in this high-
risk group could prove useful in terms of disease control 
and long term survival. Independent validation studies 
are required to prove the utility of IL-1α expression as 
a biomarker for distant metastasis in the clinical setting. 
MATERIALS AND METHODS
Patients
The biopsies used in the present study were obtained 
from 154 consecutive patients with a pathologically 
confirmed HNSCC treated at our centre between 2004 and 
2010. All the patients were evaluated by the institution’s 
cancer committee, and the decision to treat them with 
induction chemotherapy, surgery, radiotherapy or chemo-
radiotherapy was based on institutional guidelines. 
The clinical data were obtained from a database which 
prospectively collects information about the clinical 
status, tumor characteristics, treatment, and follow-up of 
all patients treated in our centre since 1985 [30].
Table 1 shows the characteristics of the patients 
included in the study. All patients had a minimum follow-
up for 2 years. The present study was approved by the 
local ethics committee, and informed consent was obtained 
from each subject. All procedures were reviewed by the 
Institutional Review Board at Hospital de la Santa Creu i 
Sant Pau. The study conforms to the principles outlined in 
the Declaration of Helsinki.
Analysis of mRNA levels
Tumor tissue samples obtained from each patient 
were stabilized by inclusion in RNA-later (Quiagen 
GmbH, Hilden, Germany) immediately after biopsy, and 
stored at -80ºC until processing. Total RNA was extracted 
using Trizol (Invitrogen, Carlsbad, CA) following the 
manufacturer’s instructions and RT-PCR was performed 
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as described previously [20]. Relative expression was 
expressed as transcript /β-actin ratios.
Determination of IL-1α released by HNSCC 
tumor samples
IL-1α secretion was analyzed in 35 tumor biopsies. 
100-200 mg tissue fragments were incubated in 0.5 mL 
of DMEM (Biological Industries, Kibbutz Beit Haemek, 
Israel) for 48 h in a cell incubator. Culture medium was 
then recovered and kept at −80º C until IL-1α analysis.
Tumor cell culture
SCC-9 (CRL-1629, tongue carcinoma) and SCC-
4 (CRL-1624, tongue carcinoma) were obtained from 
American Type Culture Collection (ATCC) and cultured 
as recommended by the supplier.
Isolation and culture of human microvascular 
endothelial cells (MVEC)
MVEC were isolated from human adult foreskins 
as previously described [27, 31]. All experimental studies 
were performed with Dynabeads CD31-purified MVEC 
passage 2 to passage 6.
Analysis of IL-1α and IL-1β proteins
Quantitative analysis of IL-1α and IL-1β in 
the culture media was performed by specific ELISA 
following the manufacturer’s instructions; IL-1α was from 
R&D Systems (Minneapolis, MN) and IL-1β was from 
eBioscience (San Diego, CA).
Plasmid/siRNA transfection of tumoral cells
Silencer predesigned siRNA targeting IL-1α 
(ID:s7266) or Silencer™ Negative Control#1 siRNA 
(ID:4390843) used in knockdown experiments were 
obtained from Ambion. Plasmid encoding full-length IL-1α 
pCMV6-IL-1α (SC324639) and the control empty vector 
pCMV6-AC (PS100020) were purchased from Origene 
Technologies (Rockville, MD). siRNA and plasmids were 
transfected using Nucleofector™ technology (Amaxa Inc) 
with the “Amaxa Cell Line Nucleofector kit V” according 
to the manufacturer’s recommendations [32]. Briefly, 
3-5 x 106 log phase cells were suspended in 100 μL of 
Nucleofector Solution V, mixed with 3 μg of siRNA or 
plasmid DNA, and electroporated with the program X-001. 
After electroporation, cells were suspended in 500 µL of 
pre-warmed cell culture medium and seeded in complete 
medium for 6 h after which the medium was changed 
to serum-free medium containing 0.5% BSA. Gene 
knockdown and overexpression was verified measuring 
IL-1α in the cell culture supernatants by ELISA.
Tumoral cells adhesion and trans-endothelial 
migration assays
Tumoral cells starved overnight in serum-free 
medium containing 0.5% BSA were harvested and 
suspended in PBS at a cell density of 1×106 cells/mL. 
1,1_-dioctadecyl-3,3,3_,3_-tetramethyl-indocarbocyanine 
perchlorate (Dil, Sigma) in ethanol was added to yield a 
10 μg/mL final concentration and incubated for 1 hour at 
37ºC. After washing twice with serum-free medium, cells 
were suspended in DMEM containing 0.5% BSA at the 
adequate cell density.
For the adhesion assay, MVEC cultured in 12-well 
cell culture plates until confluence was reached were 
treated or not with IL-1β for 24 hours in MCDB containing 
1% SBF. MVEC were washed twice before the addition of 
0.5 mL of DMEM with 1% FBS and warmed at 37ºC for 
5 minutes before the addition of 1×106 labeled tumoral 
cells suspended in 0.5 mL of medium. The cells were then 
incubated at 37ºC for 30 minutes. Thereafter, non-adherent 
cells were thoroughly washed with PBS and 150 μL of 1% 
Triton X-100 was added to each well. Fluorescence was 
measured in a Synergy™ HT Multi-Detection Microplate 
Reader (Biotek) using a 530/590 filter set. Cell number 
was determined by running a fluorescent cell dose curve 
for each assay.
For the trans-endothelial migration assays, MVEC 
were plated onto 24-well Millicell cell culture inserts 
8-µm PET (Millipore, Billerica, MA) and allowed to form 
a confluent monolayer. Once confluence was reached, the 
culture medium from the inserts was removed and the 
inserts were transferred to new wells containing 600 µL 
of serum-free DMEM 0.5% BSA. 2.5×105 of fluorescent 
labeled tumoral cells in 0.25 mL of medium were added to 
the upper well of the inserts in the presence or the absence 
of 250 ng/mL recombinant human IL-1Ra and allowed to 
transmigrate through the endothelium for 24 h. Thereafter, 
non-migratory cells were removed by aspirating and 
inserts were placed into new wells containing 0.5 % 
trypsin in PBS. Cells were completely dislodged from the 
underside of the membrane by gentle tilting. They were 
then centrifuged and lysed. Fluorescence was measured 
as for adhesion assays. 
Statistical analysis
When data fitted a normal distribution, the Student 
t-test was used to compare groups. The Mann-Whitney 
Rank Sum Test was used when normality failed. To 
determine the association between variables, data were 
Log10 transformed to normalize their distribution, and 
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the Pearson Product Moment Correlation method was then 
used. A “p” value below 0.05 was considered significant. 
The continuous value of the mRNA expression level of 
IL-1α was categorized using a classification and regression 
tree (CART) method, considering the appearance 
of distant metastasis as the dependent variable. The 
actuarial adjusted survival free of distant metastasis was 
calculated using the Kaplan-Meier method. Differences in 
survival rates between categories defined by CART were 
compared by the log-rank test. A multivariate analysis 
was made using Cox’s proportional hazard regression 
analysis. The dependent variable was distant metastasis-
free survival, and the independent variables were 
location of the primary tumor (oral cavity-oropharynx 
versus larynx-hypopharynx), local extension (T1-2 
versus T3-4), regional extension (N0 versus N+), type 
of treatment (surgery± radiotherapy versus radiotherapy/ 
chemoradiotherapy), and category of IL-1α as defined 
by CART. SPSS and Sigma-Plot software were used for 
statistical analysis.
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